PROGRAM OBJECTIVES:
Provide product overview including indication, important safety information, dosing, and administration
Review clinical trial results including patient preference data Please note that this is a promotional educational program; CME credit will not be available.
INDICATIONS
EARLY BREAST CANCER
PHESGOTM (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for
• the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage
breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for
early breast cancer (EBC)
• the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence
Select patients for therapy based on an FDA-approved companion diagnostic test.
METASTATIC BREAST CANCER PHESGOTM is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic test.
Comments